"IMR-32人神經(jīng)母細(xì)胞瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長(zhǎng)特性：貼壁生長(zhǎng)

【細(xì)胞培養(yǎng)經(jīng)驗(yàn)分享】啟蒙老師的重要性：一般進(jìn)實(shí)驗(yàn)室都有師兄師姐帶著做，他們就是你做細(xì)胞的啟蒙老師。他們的操作手法、細(xì)節(jié)、理論講解就成了你操作的準(zhǔn)則，如營(yíng)養(yǎng)液、細(xì)胞瓶的擺放位置、滅菌處理程序、開蓋手法、細(xì)胞吹打手法等等。要學(xué)會(huì)他們的正確操作，在第一次的時(shí)候就要重視。像養(yǎng)孩子一樣養(yǎng)細(xì)胞，細(xì)胞有時(shí)真的很脆弱，最好每天都去看看它，以防止出現(xiàn)培養(yǎng)箱缺水、缺二氧化碳、停電、溫度不夠等異?，F(xiàn)象，也好及時(shí)解決這些意外，避免重復(fù)實(shí)驗(yàn)帶來的更大痛苦。好細(xì)胞要及時(shí)保種：細(xì)胞要分批傳代，這樣即使有一批出了問題，還有一批備用的。像后者一般人可能不容易做到。但這是我血的教訓(xùn)，有一次細(xì)胞污染了，全軍覆沒。當(dāng)時(shí)可后悔沒有保種。細(xì)胞跟人一樣，不同的細(xì)胞，培養(yǎng)特性是不一樣的。培養(yǎng)過程中要細(xì)細(xì)體會(huì)，不同細(xì)胞系使用不同的培養(yǎng)基和血清。

換液周期：每周2-3次

GC-1 Cells;背景說明：精原細(xì)胞；SV４０轉(zhuǎn)化；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Normal Rat Kidney-52E細(xì)胞、Hs 695T細(xì)胞、GM05372E細(xì)胞

LS411 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；每周２次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：H-2195細(xì)胞、NCI-H1668細(xì)胞、HCC1954細(xì)胞

NCI-H1688 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MOLT3細(xì)胞、P 3 HR 1細(xì)胞、CCD 1112SK細(xì)胞

IMR-32人神經(jīng)母細(xì)胞瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：是一種人類神經(jīng)母細(xì)胞瘤細(xì)胞系，來源于一名患有神經(jīng)母細(xì)胞瘤的兒童患者的骨髓標(biāo)本。神經(jīng)母細(xì)胞瘤是一種起源于交感神經(jīng)系統(tǒng)的惡性腫瘤，主要發(fā)生在兒童中。是由W·W·Nichols、J·Lee和S·Dwight于1967年4月從一位13個(gè)月大的男嬰下腹部腫瘤中分離建系。診斷認(rèn)為是神經(jīng)母細(xì)胞瘤，并有少部分區(qū)域的器質(zhì)性分化。

┈訂┈購(gòu)(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號(hào)】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

貼壁細(xì)胞的傳代培養(yǎng)，詳細(xì)步驟如下：首先倒掉培養(yǎng)基，在這一步驟可以收集一些細(xì)胞上清做支原體檢測(cè)；加入胰蛋白酶，一般T25是加2mL，蓋好瓶蓋，搖晃T25培養(yǎng)瓶，使胰蛋白酶均勻覆蓋在細(xì)胞表面，放入培養(yǎng)箱2-3min，期間可在顯微鏡下觀察，看到大部分細(xì)胞變圓，即可放入超凈臺(tái)，加入2倍的完全培養(yǎng)基，這里就是加4mL培養(yǎng)基，終止消化；將含有胰蛋白酶，細(xì)胞和培養(yǎng)基一起轉(zhuǎn)移到離心管中，1000rpm/3min離心，去掉上清；新鮮的完全培養(yǎng)基重懸，根據(jù)細(xì)胞的生長(zhǎng)特性和后續(xù)的實(shí)驗(yàn)需求進(jìn)行傳代，比如我養(yǎng)的Hepa1-6就長(zhǎng)的比較快，不是著急用的話，我就會(huì)按1E6個(gè)細(xì)胞/T75培養(yǎng)瓶進(jìn)行傳代；但如果后兩天要用，就會(huì)適當(dāng)多傳一點(diǎn)；還可通過顯微鏡計(jì)數(shù)后，直接用于細(xì)胞鋪板，繼續(xù)后續(xù)的實(shí)驗(yàn)。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫(kù)

IMR-32人神經(jīng)母細(xì)胞瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來源：人源、鼠源等其它物種來源

NCI-H1869 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：４傳代；每周換液２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：LS-1034細(xì)胞、ssMCF7細(xì)胞、TGHAVSMC細(xì)胞

Hce8693 Cells;背景說明：盲腸腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：UPCI-SCC-154細(xì)胞、ME-1 [Human leukemia]細(xì)胞、CMT-167細(xì)胞

SW-948 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：５傳代，每周換液１-２次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：SW 1573細(xì)胞、CL-34細(xì)胞、SKG-3a細(xì)胞

HEC-1A Cells;背景說明：這株細(xì)胞及其亞株HEC-１-B是H.Kuramoto及其同事１９６８年從一位IA期子宮內(nèi)膜癌患者身上分離得到的。PAF可以誘導(dǎo)其c-fos的表達(dá)。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長(zhǎng)滿;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Oka-C1細(xì)胞、SK Col 1細(xì)胞、OEC33細(xì)胞

┈訂┈購(gòu)(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號(hào)】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：成纖維細(xì)胞樣

細(xì)胞培養(yǎng)無(wú)菌操作步驟和注意事項(xiàng)：１.打開無(wú)菌工作臺(tái)及凈化室的紫外燈，消毒半小時(shí)以上。２.進(jìn)入凈化室前先關(guān)閉紫外燈，打開超凈臺(tái)風(fēng)機(jī)，等待３０min以上，以排盡臭氧。３.穿HAO隔離衣，戴HAO口罩，帽子。４.風(fēng)淋２分鐘。５.０.１%水泡手，擦干。６.點(diǎn)燃酒精燈;超凈臺(tái)內(nèi)應(yīng)避免放入過多的物品;使用的吸管，滴管，試管，培養(yǎng)瓶等均事先滅菌。７.打開各類瓶蓋前先過火，以固定灰塵;打開的瓶口、試管口過火焰，鑷子使用前應(yīng)經(jīng)火焰燒灼。８.水平式風(fēng)機(jī)的超凈臺(tái)，應(yīng)使瓶口斜置，應(yīng)盡量避免瓶口敞開直立。９.同一根吸管或滴管不應(yīng)連續(xù)用于幾個(gè)不同的細(xì)胞系；吸取培養(yǎng)基的吸管應(yīng)離開培養(yǎng)瓶或試管口０.５cm，避免伸入培養(yǎng)瓶口或試管口；以防止細(xì)胞系的互相混雜污染。１０.漏在培養(yǎng)瓶上或臺(tái)上的體，立即用酒精棉球擦凈。１１.操作完畢后恢復(fù)工作臺(tái)面。

Hs683T Cells;背景說明：該細(xì)胞源自７６歲白人男性的左顳葉側(cè)膠質(zhì)瘤組織，有微絨毛，無(wú)橋粒。 ;傳代方法：１：４傳代，每周換液２次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：H1836細(xì)胞、PBL細(xì)胞、HTori3細(xì)胞

TGHAVSMC Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCC70細(xì)胞、Hs839.T細(xì)胞、Raji細(xì)胞

NCIH1876 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：OP-9細(xì)胞、HO1-N1細(xì)胞、NCI H2106細(xì)胞

HBVP Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH1793細(xì)胞、Panc-8_13細(xì)胞、Reuber H35細(xì)胞

WB-F344 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：NCI-H211細(xì)胞、Kit225/K6細(xì)胞、WM239A細(xì)胞

Y3.AG.1.2.3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Rat Fetal Lung-6細(xì)胞、MES-SA/Dx5細(xì)胞、TALL 1細(xì)胞

HT115 Cells;背景說明：結(jié)腸癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OCI-AML-5細(xì)胞、SNU5細(xì)胞、SKMEL3細(xì)胞

HCC1419 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Lymph Node Carcinoma of the prostate細(xì)胞、LC-1Sq細(xì)胞、SK-RC 52細(xì)胞

SU-86-86 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCA 7細(xì)胞、NCIH820細(xì)胞、OVCA8細(xì)胞

MDA-MB468 Cells;背景說明：該細(xì)胞是１９７７年由CailleauR等從一位患有轉(zhuǎn)移性乳腺癌的５１歲黑人女性的胸腔積液中分離得到的。雖然供體組織的G６PD等位基因雜合，但此細(xì)胞株始終表現(xiàn)為G６PDA表型。P５３基因２７３位密碼子存在G→A突變，從而導(dǎo)致Arg→His替代。每個(gè)細(xì)胞上存在１×１０６個(gè)EGF受體。;傳代方法：１：２-１：４傳代；２-３天換液１次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MDA MB 453細(xì)胞、A375S2細(xì)胞、U-343MG細(xì)胞

ME1 Cells;背景說明：急性髓系白血?。荒行?傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TE9細(xì)胞、Tb 1 Lu (NBL-12)細(xì)胞、NCI-H2228細(xì)胞

OC316 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：COLO320HSR細(xì)胞、WEHI-279細(xì)胞、Human Embryo Kidney-2細(xì)胞

C-4-I Cells;背景說明：宮頸鱗癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Capan2細(xì)胞、beta-TC6細(xì)胞、Jijoye細(xì)胞

BNL-CL.2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NW-MEL-38細(xì)胞、HSF細(xì)胞、P31-FUJ細(xì)胞

HR-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每２-３天換液;生長(zhǎng)特性：懸浮生長(zhǎng) ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：HEK293F細(xì)胞、Walker-256-TC細(xì)胞、SNU638細(xì)胞

MDA-435 Cells;背景說明：乳腺癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：GA-10 (Clone 4)細(xì)胞、SK-RC-20細(xì)胞、F-36P細(xì)胞

H-740 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：UACC 812細(xì)胞、H-1436細(xì)胞、HNE-2細(xì)胞

308TAg Cells(提供STR鑒定圖譜)

Abcam HeLa STS KO Cells(提供STR鑒定圖譜)

AH129-N1 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRJ021 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XJ139 Cells(提供STR鑒定圖譜)

C2190 Cells(提供STR鑒定圖譜)

DA00190 Cells(提供STR鑒定圖譜)

EMT6/AR1 Cells(提供STR鑒定圖譜)

GM05972 Cells(提供STR鑒定圖譜)

BT483 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代，２—３天換液一次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：SN-12C細(xì)胞、RPMI8226/S細(xì)胞、NCI-H1648細(xì)胞

IMR-32人神經(jīng)母細(xì)胞瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

KP-N-RT Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成神經(jīng)細(xì)胞;相關(guān)產(chǎn)品有：NCIH1563細(xì)胞、Ca-Ski細(xì)胞、HG2855細(xì)胞

JB6 [Mouse] Cells;背景說明：表皮；自發(fā)永生；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NRK49F細(xì)胞、CL1-5細(xì)胞、ST-2細(xì)胞

Chinese Hamster Lung Cells;背景說明：廣泛應(yīng)用于染色體異常測(cè)試。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：H-1568細(xì)胞、PNT1-a細(xì)胞、COLO-320-DM細(xì)胞

SW-1271 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HeLa/S3細(xì)胞、HEK293T/17細(xì)胞、DLD 1細(xì)胞

Swiss/3T3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Human Fetal Thymocyte-8810細(xì)胞、LL/2 (LLC1)細(xì)胞、NCI-H2085細(xì)胞

Abcam RAW 264.7 Prkaa1 KO Cells(提供STR鑒定圖譜)

RPMI 7951 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：X63.Ag8.653細(xì)胞、BEAS 2B細(xì)胞、SU-DHL-4細(xì)胞

NCI-H125 Cells;背景說明：腺鱗狀肺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：J82COT細(xì)胞、SKMEL28細(xì)胞、HT144-mel細(xì)胞

Hs940.T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代，２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：293 HEK細(xì)胞、UMNSAH-DF 1細(xì)胞、IGROV細(xì)胞

HEK/EBNA Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：１０傳代；每周２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：K 562細(xì)胞、HT3細(xì)胞、NCI-H1693細(xì)胞

ZR75-1 Cells;背景說明：該細(xì)胞產(chǎn)生高水平的黏液素MUC-１ mRNA，低水平的MUC-２ mRNA，但不表達(dá)MUC-３基因；表達(dá)雌激素受體。;傳代方法：１：４-１：６傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MSB-1細(xì)胞、SF126細(xì)胞、Large Cell Lung Cancer-103H細(xì)胞

TE-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：OC316細(xì)胞、Sf-21細(xì)胞、HCC-1395細(xì)胞

NCIH2073 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代 ;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：BCECs細(xì)胞、L23/P細(xì)胞、ECC1細(xì)胞

Lu-165 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEY A8細(xì)胞、HuO9細(xì)胞、HCC 70細(xì)胞

GM28955 Cells(提供STR鑒定圖譜)

HAP1 PEX5 (-) 5 Cells(提供STR鑒定圖譜)

KMH-2 Cells;背景說明：未分化甲狀腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OCI-Ly1細(xì)胞、SJRH-30細(xì)胞、aTC1 Clone 6細(xì)胞

M-1 Cells;背景說明：腎集合管；SV４０轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEEpiC細(xì)胞、MD Anderson-Metastatic Breast-415細(xì)胞、RPMI7951細(xì)胞

HCC-1171 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MCF-10A細(xì)胞、LNCaP.FGC細(xì)胞、FDC-P1細(xì)胞

M20 [Human melanoma] Cells;背景說明：黑色素瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WM115細(xì)胞、MeT5A細(xì)胞、SUM 159細(xì)胞

Jiyoye Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周２-３次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：ABC-1細(xì)胞、LNCaP C4-2細(xì)胞、3AO細(xì)胞

Ramos Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CAL51細(xì)胞、PC-9細(xì)胞、C32 mel細(xì)胞

HEC-1B Cells;背景說明：該細(xì)胞是H.Kuramoto１９６８年分離的HEC-１-A細(xì)胞亞株。不同於HEC-A-１的是：該亞株在培養(yǎng)第１３５天到１９０天之間表現(xiàn)出穩(wěn)定的生長(zhǎng)周期，且重現(xiàn)扁平，與親本細(xì)胞系相比更具鋪路石式樣。此外主要染色體組是親本細(xì)胞的兩倍。;傳代方法：１：３傳代，２-３天換液一次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HPB/ALL細(xì)胞、SW-982細(xì)胞、H226細(xì)胞

NCIH1435 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代，每周換液２-３次;生長(zhǎng)特性：貼壁生長(zhǎng)，松散;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CHG-5細(xì)胞、293-GP細(xì)胞、JIII細(xì)胞

HsBt Cells(提供STR鑒定圖譜)

KOLF2.1J SNCA A30G SNV/WT Cells(提供STR鑒定圖譜)

MOLT-12 Cells(提供STR鑒定圖譜)

NYSCF-051024-01-MR Cells(提供STR鑒定圖譜)

RG-334 Cells(提供STR鑒定圖譜)

UCSD233i-SAD2-2 Cells(提供STR鑒定圖譜)

ZZUNEUi004-A Cells(提供STR鑒定圖譜)

HG01579 Cells(提供STR鑒定圖譜)

Sf21 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：U-251_MG細(xì)胞、NHRF細(xì)胞、HT-3細(xì)胞

ML-2 Cells;背景說明：急性髓單核細(xì)胞白血病；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CAMA細(xì)胞、H2452細(xì)胞、NCIH508細(xì)胞

BIC Cells;背景說明：食管腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H1563細(xì)胞、Adeno 293細(xì)胞、Panc-3_27細(xì)胞

BJAB-1 Cells;背景說明：Burkitt's淋巴瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SF767細(xì)胞、SkMel31細(xì)胞、Hs739T細(xì)胞

HCC1419 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Lymph Node Carcinoma of the prostate細(xì)胞、LC-1Sq細(xì)胞、SK-RC 52細(xì)胞

HCC1419 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Lymph Node Carcinoma of the prostate細(xì)胞、LC-1Sq細(xì)胞、SK-RC 52細(xì)胞

T9 Cells;背景說明：膠質(zhì)瘤；Fischer ３４４;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PLA801D細(xì)胞、CWR22-R1細(xì)胞、NCIH250細(xì)胞

MD Anderson-Metastatic Breast-175-VIII Cells;背景說明：該細(xì)胞源自一位５４歲患有乳腺導(dǎo)管癌白人女性的胸腔積液。;傳代方法：１：２—１：６傳代，每周換液２—３次;生長(zhǎng)特性：松散貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：LM TK negative細(xì)胞、MDAMB175細(xì)胞、OVCAR 5細(xì)胞

U031 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代；２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HEL299細(xì)胞、NCIH1385細(xì)胞、CCF-STTG1細(xì)胞

Panc04.03 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：NK92細(xì)胞、NF639細(xì)胞、Rabbit Kidney 13細(xì)胞

HcaF Cells;背景說明：肝癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H8細(xì)胞、YD-15細(xì)胞、RT-112細(xì)胞

HCC1395 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代，每周換液２—３次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：COLO-829細(xì)胞、3T6細(xì)胞、Human Fetal Thymocyte-8810細(xì)胞

RT4 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，每周２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：多角 ;相關(guān)產(chǎn)品有：U-118-MG細(xì)胞、OLN 93細(xì)胞、SVOG細(xì)胞

Cloudman M3 Cells;背景說明：黑色素瘤；雄性；DBA;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Dami細(xì)胞、Hs600T細(xì)胞、H1650細(xì)胞

BEP2D Cells;背景說明：支氣管；上皮細(xì)胞；HPV１８轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HuT102細(xì)胞、HFL-I細(xì)胞、LS-1034細(xì)胞

STSAR-21 Cells(提供STR鑒定圖譜)

HT-144 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８?jìng)鞔?，?３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：RMC-1細(xì)胞、SU-DH-L5細(xì)胞、Line 522細(xì)胞

TF-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：維持細(xì)胞濃度在３×１０４-５×１０５ cells/ml；２-３天換液１次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣　;相關(guān)產(chǎn)品有：Chang liver細(xì)胞、Alexander cells細(xì)胞、hTERT RPE1細(xì)胞

A2058 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：６-１：１２傳代，２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：SW-480細(xì)胞、AMC-HN8細(xì)胞、A7r5細(xì)胞

18G3.cl 1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SNU-216細(xì)胞、NCI H157細(xì)胞、SKGIIIA細(xì)胞

U-138 MG Cells;背景說明：星形細(xì)胞瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH196細(xì)胞、A549/DDP細(xì)胞、VMRCRCZ細(xì)胞

GAK Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：８.４ x １０^４ cells / sq.cm.;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：RSC-364細(xì)胞、C-28I2細(xì)胞、SVEC4-10細(xì)胞

IMR-32人神經(jīng)母細(xì)胞瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

SU-86-86 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCA 7細(xì)胞、NCIH820細(xì)胞、OVCA8細(xì)胞

Tu212 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：FOX-NY細(xì)胞、RT4P細(xì)胞、H-1436細(xì)胞

SKMEL24 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：星形的;相關(guān)產(chǎn)品有：32D clone 3細(xì)胞、UMNSAH/DF-1細(xì)胞、RGC6細(xì)胞

H2.35 Cells;背景說明：肝；SV４０轉(zhuǎn)化；雌性；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LNT-229細(xì)胞、RBSMC細(xì)胞、L-540細(xì)胞

SW1990 Cells;背景說明：胰腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SNU1040細(xì)胞、Hs 675.T細(xì)胞、hTERT-HPNE細(xì)胞

SW-1222 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SEG1細(xì)胞、F56 [Human neoplasm]細(xì)胞、SK-MEL-31細(xì)胞

CALU1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：消化１０分鐘。１：２。３-４天長(zhǎng)滿;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：H3255細(xì)胞、Colo205細(xì)胞、IAR-20細(xì)胞

CA-OV-3 Cells;背景說明：該細(xì)胞１９７６年建系，源自一位５４歲白人女性的卵巢腺癌組織。;傳代方法：１：３傳代，２—３天換液一次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：TC7細(xì)胞、UACC812細(xì)胞、IMR 90細(xì)胞

BayGenomics ES cell line RRI045 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XH474 Cells(提供STR鑒定圖譜)

ES[MC1R(20):tetUgp2(20)] Cells(提供STR鑒定圖譜)

NAT1(-/-)ES(B2) Cells(提供STR鑒定圖譜)

UIC2/A Cells(提供STR鑒定圖譜)

MC116 Cells(提供STR鑒定圖譜)

" "PubMed=71759; DOI=10.1126/science.71759

Balaban-Malenbaum G.B., Gilbert F.

Double minute chromosomes and the homogeneously staining regions in chromosomes of a human neuroblastoma cell line.

Science 198:739-741(1977)

PubMed=327080; DOI=10.1093/jnci/59.1.221

Fogh J., Fogh J.M., Orfeo T.

One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.

J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209

Fogh J., Wright W.C., Loveless J.D.

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=922665; DOI=10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1

Brodeur G.M., Sekhon G.S., Goldstein M.N.

Chromosomal aberrations in human neuroblastomas.

Cancer 40:2256-2263(1977)

CLPUB00387

Coriell L.L., Greene A.E., Mulivor R.A.

The human genetic mutant cell repository: list of genetic variants, chromosomal aberrations and normal cell cultures submitted to the repository. 7th edition. October 1980.

(In misc. document) Institute for Medical Research (Camden, N.J.) NIH 80-2011; pp.1-254; National Institutes of Health; Bethesda; USA (1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239

Wright W.C., Daniels W.P., Fogh J.

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7253718; DOI=10.1016/0047-6374(81)90027-0

Das N.K., Murphy D.G.

The National Institute on Aging repository cell cultures.

Mech. Ageing Dev. 16:1-17(1981)

PubMed=7459858

Rousset M., Zweibaum A., Fogh J.

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Cancer Res. 41:1165-1170(1981)

PubMed=7037175

Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.

Selective toxicity of 6-hydroxydopamine and ascorbate for human neuroblastoma in vitro: a model for clearing marrow prior to autologous transplant.

Cancer Res. 42:1331-1336(1982)

PubMed=7139592; DOI=10.1016/0165-4608(82)90105-4

Gilbert F., Balaban-Malenbaum G.B., Moorhead P.S., Bianchi D., Schlesinger H.R.

Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines.

Cancer Genet. Cytogenet. 7:33-42(1982)

DOI=10.1016/B978-0-12-008304-6.50015-4

Biedler J.L., Meyers M.B., Spengler B.A.

Homogeneously staining regions and double minute chromosomes, prevalent cytogenetic abnormalities of human neuroblastoma cells.

(In book chapter) Advances in cellular neurobiology, Vol. 4; Fedoroff S., Hertz L. (eds.); pp.267-307; Academic Press; New York; USA (1983)

PubMed=6401685; DOI=10.1007/BF02617989

Halton D.M., Peterson W.D. Jr., Hukku B.

Cell culture quality control by rapid isoenzymatic characterization.

In Vitro 19:16-24(1983)

PubMed=6888561; DOI=10.1038/305245a0

Schwab M., Alitalo K., Klempnauer K.-H., Varmus H.E., Bishop J.M., Gilbert F., Brodeur G.M., Goldstein M.N., Trent J.M.

Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour.

Nature 305:245-248(1983)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=3698005

Bregman M.D., Funk C., Fukushima M.

Inhibition of human melanoma growth by prostaglandin A, D, and J analogues.

Cancer Res. 46:2740-2744(1986)

PubMed=2535691

Ciccarone V.C., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A.

Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages.

Cancer Res. 49:219-225(1989)

PubMed=8221663

Komuro H., Hayashi Y., Kawamura M., Hayashi K., Kaneko Y., Kamoshita S., Hanada R., Yamamoto K., Hongo T., Yamada M., Tsuchida Y.

Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas.

Cancer Res. 53:5284-5288(1993)

PubMed=8490657; DOI=10.1038/ng0193-62

The I., Murthy A.E., Hannigan G.E., Jacoby L.B., Menon A.G., Gusella J.F., Bernards A.

Neurofibromatosis type 1 gene mutations in neuroblastoma.

Nat. Genet. 3:62-66(1993)

DOI=10.1016/B978-0-12-333530-2.50006-X

Israel M.A., Thiele C.J.

Tumor cell lines of the peripheral nervous system.

(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York; USA (1994)

PubMed=7838528

Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A., Speleman F., Versteeg R.

Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification.

Oncogene 10:291-297(1995)

PubMed=8665486; DOI=10.1016/0304-3835(96)04250-4

Diccianni M.B., Chau L.S., Batova A., Vu T.Q., Yu A.L.-T.

The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance.

Cancer Lett. 104:183-192(1996)

PubMed=9201287

Cinatl J. Jr., Hernaiz Driever P., Cinatl J., Ruckert D.G., Gumbel H.O.C., Rabenau H.F., Kornhuber B., Doerr H.-W.

Increased efficacy of aphidicolin killing of human neuroblastoma cells in vitro by encapsulation in liposomes.

Neoplasma 44:91-95(1997)

PubMed=9283597; DOI=10.1016/S0165-4608(96)00362-7

Van Roy N., Jauch A., Van Gele M., Laureys G., Versteeg R., De Paepe A., Cremer T., Speleman F.

Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines.

Cancer Genet. Cytogenet. 97:135-142(1997)

PubMed=9516836; DOI=10.1016/S0959-8049(97)00319-5

Van Roy N., Laureys G., Van Gele M., Opdenakker G., Miura R., van der Drift P., Chan A., Versteeg R., Speleman F.

Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes.

Eur. J. Cancer 33:1974-1978(1997)

DOI=10.1007/0-306-46872-7_2

Thiele C.J.

Neuroblastoma.

(In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York; USA (1999)

PubMed=11550280; DOI=10.1002/gcc.1174

Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B., Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.

Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines.

Genes Chromosomes Cancer 32:126-135(2001)

PubMed=11668190; DOI=10.1177/002215540104901105

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

Immunocytochemical analysis of cell lines derived from solid tumors.

J. Histochem. Cytochem. 49:1369-1378(2001)

PubMed=12210830; DOI=10.1002/jnr.10330

Yoshida S., Narita T., Taga T., Ohta S., Takeuchi Y.

Malignant rhabdoid tumor shows incomplete neural characteristics as revealed by expression of SNARE complex.

J. Neurosci. Res. 69:642-652(2002)

PubMed=12702577

Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A., Sugimoto T., Inazawa J.

PPM1D is a potential target for 17q gain in neuroblastoma.

Cancer Res. 63:1876-1883(2003)

PubMed=15390183; DOI=10.1002/gcc.20096

Gebauer S., Yu A.L.-T., Omura-Minamisawa M., Batova A., Diccianni M.B.

Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma.

Genes Chromosomes Cancer 41:297-308(2004)

PubMed=15892104; DOI=10.1002/gcc.20198

Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K.A., Khazi D., Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L., Maris J.M.

High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.

Genes Chromosomes Cancer 43:390-403(2005)

PubMed=16524757; DOI=10.1016/j.biocel.2006.01.007

Fry D.G., Dayton B.D., Brodjian S.J., Ogiela C., Sidorowicz H., Frost L.J., McNally T., Reilly R.M., Collins C.A.

Characterization of a neuronal cell line expressing native human melanin-concentrating hormone receptor 1 (MCHR1).

Int. J. Biochem. Cell Biol. 38:1290-1299(2006)

PubMed=16822308; DOI=10.1186/1471-2407-6-177; PMCID=PMC1533846

Dam V., Morgan B.T., Mazanek P., Hogarty M.D.

Mutations in PIK3CA are infrequent in neuroblastoma.

BMC Cancer 6:177.1-177.10(2006)

PubMed=17974978; DOI=10.1158/0008-5472.CAN-06-4345

Xue C.-Y., Haber M., Flemming C., Marshall G.M., Lock R.B., MacKenzie K.L., Gurova K.V., Norris M.D., Gudkov A.V.

p53 determines multidrug sensitivity of childhood neuroblastoma.

Cancer Res. 67:10351-10360(2007)

PubMed=20655465; DOI=10.1016/j.cell.2010.06.004; PMCID=PMC2913027

Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H.N., Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C., Messiaen L.M., Versteeg R., Bernards R.

NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.

Cell 142:218-229(2010)

PubMed=22213050; DOI=10.1002/ijc.27415; PMCID=PMC3757132

Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J., Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.

PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.

Int. J. Cancer 131:1556-1568(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=24466371; DOI=10.1593/tlo.13544; PMCID=PMC3890703

Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J., Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A., Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.

Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.

Transl. Oncol. 6:685-696(2013)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314; PMCID=PMC4404347

Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.

A mass spectrometric-derived cell surface protein atlas.

PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=28350380; DOI=10.1038/sdata.2017.33; PMCID=PMC5369315

Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L., Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.

Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.

Sci. Data 4:170033-170033(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)"